Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209937 | 0.73 | PRNP (0.54) | BRD4L3MBTL1PRNPNPSR1RXFP1 | |
| SCHEMBL15452664 | 0.73 | MEN1 (0.46) | KDM4EFLT1KDRMAOBHTT | |
| SCHEMBL28211667 | 0.71 | L3MBTL1 (0.60) | KDM4EL3MBTL1HTTPRNPNPSR1 | |
| SCHEMBL7044638 | 0.71 | PDE10A (0.51) | BRD4KDM4EL3MBTL1SMN1; SMN2HTT | |
| SCHEMBL31682474 | 0.71 | L3MBTL1 (0.60) | KDM4EL3MBTL1HTTPRNPNPSR1 | |
| SCHEMBL28175543 | 0.70 | KMT2A (0.62) | KDM4EL3MBTL1MAOBSMN1; SMN2HTT | |
| SCHEMBL27313299 | 0.69 | DCPS (0.55) | KDM4ESMN1; SMN2HTTRAB9ANPSR1 | |
| SCHEMBL8568154 | 0.68 | L3MBTL1 (0.73) | KDM4EL3MBTL1SMN1; SMN2HTTRAB9A | |
| SCHEMBL28915374 | 0.68 | POLB (0.57) | KDM4EL3MBTL1SMN1; SMN2RAB9ARXFP1 | |
| SCHEMBL30309907 | 0.67 | PLK1 (0.43) | KDM4EKDRSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234324-A1 | Quinazolinamide derivatives | HSP90AB1, HSP90AA1, HSP90AB2P | BRD4 498/4885KDM4E 3277/4885L3MBTL1 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.